Sie befinden sich hier

Inhalt

Publications

A list of Prof. Dr. Adelheid Cerwenka's publications can be also found on PubMed.

1993

1. Schwarz M, Sunder-Plaßmann R, Cerwenka A, Pickl WF and Holter W. Regulation der Zytokinproduktion humaner T-Lymphozyten in der allergischen Immunantwort, Wien. Klin. Wochenschrift. 105/23: 672-676, 1993

1994

2. Cerwenka A, Bevec D, Majdic O, Knapp W, and Holter W. TGF-b1 is a potent inducer of human effector T cells. J. Immunol. 153: 4367-4377, 1994

1995

3. Pickl WF, Sunder-Plassmann R, Majdic O, Schwarz M, Cerwenka A, Knapp W and Holter W. T6.9 Determination of discrete activation signals to peripheral blood mononuclear cells delivered by mAb of the E-rosetting/GPI-anchored Workshop Adhesion Structures Subpanel 1, Leukocyte Typing V, Oxford University Press; 1995; page 323, 1995

4. Böhmig GA, Csmarits B, Cerwenka A, Alaei P, Kovarik J and Zlabinger GJ. Induction of alloantigen-specific hyporesponsiveness in vitro by the short chain fatty acid n-butyrate. Transplantation. 59: 1500-1503, 1995

1996

5. Holter W, Schwarz M, Cerwenka A and Knapp W. The role of CD2 as a regulator of human T cell cytokine production, Immunol. Rev. 153: 107-122, 1996

6. Tsitoura DC, Holter W, Cerwenka A, Gelder CM and  Lamb JR. Induction of anergy in T helper 0 cells by stimulation with altered T cell antigen receptor ligands. J. Immunol. 156: 2801-2808, 1996

7. Cerwenka A, Kovar H, Majdic O and Holter W. Fas- and activation-induced apoptosis are reduced in human T cells preactivated in the presence of TGF-b. J. Immunol. 156: 459-464, 1996

1998

8. Cerwenka A, Carter LL, Reome JB, Swain SL and Dutton RW. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines. J. Immunol. 161: 97-105, 1998

1999

9. Cerwenka A and Swain SL. TGF-b1: Immunosuppressant and viability factor for T lymphocytes. Microbes Infect. 1 (15): 1291-6, 1999

10. Sepulveda H, Cerwenka A, Morgan T and Dutton RW. CD28, IL-2-independent costimulatory pathways for CD8 T lymphocyte activation. J. Immunol. 163: 1133-1142, 1999

11. Cerwenka A, Morgan TM and Dutton RW. Naïve, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: Homing properties rather than initial frequencies are crucial. J. Immunol. 163: 5535-43, 1999

12. Cerwenka A, Morgan TM, Harmsen AG, and Dutton RW. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J. Exp. Med. 189: 423-434, 1999

2000

13. Bakker ABH, Hoek RM, Cerwenka A, Blom B, Lucian L, McNeil T, Murray R, Phillips JH, Sedgwick JD, and Lanier LL. DAP12-deficient mice fail to develop autoimmunity due to impaired T cell priming. Immunity. 13:345-353, 2000

14. Cerwenka A, Bakker ABH,  McClanahan T, Wagner J, Wu J, Phillips JH and Lanier LL. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity. 12: 721-727, 2000

2001

15. Cerwenka H, Wolf G, Mischinger HJ, Cerwenka A, Demel U, Tilz GP. Natural killer (NK) cell deficiency and severe wound infection after thyroid surgery. Eur. J. Surg. 167:792-794, 2001

16. Wiley JA, Cerwenka A, Harkema JR, Dutton RW and Harmsen AG. Production of Interferon-g by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology. Am. J. Path. 158:119-130, 2001

17. Cerwenka A, Lanier LL. NK cells, viruses and cancer. Nature Rev. Immunol. 1:41-49, 2001

18. Cerwenka A, Lanier LL. Ligands of natural killer cell receptors: redundancy or specificity, Immunol. Rev. 181:158-169, 2001

19. O’Callaghan C, Cerwenka A, Willcox BE, Lanier LL, Bjorkman PJ. Molecular competition for NKG2D: H60 and RAE-1 compete unequally for NKG2D with dominance of H60. Immunity. 15:201-211, 2001

20. Cerwenka A, Baron JL, and Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits NK cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. (USA) 98:11521-6, 2001

2002

21. Cerwenka A, O’Callaghan CA, Hamerman JA, Yadav R, Ajayi W, Roopenian DC, Joyce S, Lanier LL. The minor histocompatibility antigen H60 peptide interacts with both H-2Kb and NKG2D. J. Immunol. 168:3131-3134, 2002

2003

22. Cerwenka A, Lanier LL. NKG2D Ligands: Unconventional MHC molecules exploited by viruses and cancer. Tissue antigens. 2003: 61 (5):335-43, 2003

2005

23. Routes JM, Ryan S, Morris K, Takaki R, Cerwenka A, Lanier LL.. Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J. Exp. Med. 202(11):1477-82, 2005

2006

24. Paschen A, Arens N, Sucker A, Greulich-Bode KM, Fonsatti E, Gloghini A, Striegel S, Schwinn N, Carbone A, Hildenbrand R, Cerwenka A, Maio M, Schadendorf D. The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin. Cancer Res.12(11 Pt 1):3297-305, 2006

25. Nausch N, Florin L, Hartenstein B, Angel P, Schorpp-Kistner M, Cerwenka A.
Cutting edge: the AP-1 subunit JunB determines NK cell-mediated target cell killing by regulation of the NKG2D-ligand RAE-1epsilon. J. Immunol. 176(1):7-11, 2006

2007

26. Tessarz AS, Weiler S, Zanzinger K, Angelisová P, Horejsí V, and Cerwenka A. NTAL negatively regulates TREM-1/DAP12 induced inflammatory cytokine production in myeloid cells. J. Immunol. 178: 1991-1999, 2007

27. Hoffmann SC, Schellack C, Wiedekind S, Konold S, Schmitz D, Cerwenka A, Pflanz S, and Watzl C. Identification of CLEC12B, an inhibitory receptor on myeloid cells. J. Biol. Chem. 282(31):22370-5, 2007

28. Cerwenka A, Falk CS, Watzl C. NK cells-from basic research to cancer therapy. Eur J  Immunol. 37(5):1161-4, 2007

2008

29. Arnon TI, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F, Galili R, Cerwenka A, Benharroch D, Sion-Vardy N, Porgador A, Mandelboim O. Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS ONE  3(5):e2150, 2008

30. Nausch N, Cerwenka A. NKG2D ligands in tumour immunity. Oncogene, 27(45):5944-58, 2008

31. Tessarz AS, Cerwenka A. The TREM-1/DAP12 pathway. Immunol. Lett. 116(2):111-6, 2008

32. Textor S, Dürst M, Janssen L, Accardi R, Tommasino M, Trunk MJ, Porgador A, Gissmann L and Cerwenka A. Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int. J .Cancer, 123(10):2343-53, 2008

33. Nausch N, Galani IE, Schlecker E and Cerwenka A. Mononuclear Myeloid-Derived “Suppressor” Cells express RAE-1 and activate NK cells. Blood. 112(10):4080-9, 2008

34. Wendel M, Galani IE, Suri-Payer E, and Cerwenka A. NK cell accumulation in tumors is dependent on IFN-g and CXCR3 ligands, Cancer Res. 68(20):8437-45, 2008

2009

35. Zanzinger K, Schellack C, Nausch N, Geginat G, Cerwenka A. TREM 1 is upregulated on inflammatory monocytes and myeloid derived suppressor cells. Immunology 128(2):185-95, 2009
36. Jarahian M, Watzl C, Fournier P, Arnold A, Djandji D, Zahedi S, Cerwenka A, Paschen A, Schirrmacher V, Momburg F., Activation of natural killer cells by Newcastle disease virus hemagglutinin-neuraminidase. J Virol 83(16):8108-21, 2009
37. Elkabets M, Krelin Y, Dotan S, Cerwenka A, Porgador A, Lichtenstein RG, White MR, Zoller M, Iwakura Y, Dinarello CA, Voronov E, Apte RN.. Host-derived interleukin-1alpha is important in determining the immunogenicity of 3-methylcholantrene tumor cells. J Immunol 182(8):4874-81, 2009

38. Schwinn N, Vokhminova D, Textor S, Sucker A, Nausch N, Tüttenberg J, Steinle A, Cerwenka A, Schadendorf D, Paschen A. Interferon- interferes with NKG2D-mediated recognition of human melanoma by down-regulating NKG2D ligand expression. Int. J. Cancer 124(7):1594-604, 2009

39. Cerwenka A. New twist on the regulation of NKG2D ligand expression. J Exp Med 206(2):265-8, 2009

2010

40. A. Cerwenka. Main Lecture, The innate immune response against cancer. European Surgery-Acta Chirurgica Austriaca 42, 3-4, 2010

41. Galani IE, Wendel M, Stojanovic A, Jesiak M, Müller MM, Schellack C, Suri-Payer E, Cerwenka A. Regulatory T cells control macrophage accumulation and activation in lymphoma. Int J Cancer 127(5):1131-40, 2010

2011

42. Stojanovic A, Cerwenka A. Natural Killer Cells and Solid Tumors. J Innate Immun. 3(4):355-64, 2011

43. Rosental B, Brusilovsky M, Hadad U, Oz D, Appel MY, Afergan F, Yossef R, Rosenberg LA, Aharoni A, Cerwenka A, Campbell KS, Braiman A, Porgador A. 2011, Proliferating Cell Nuclear Antigen Is a Novel Inhibitory Ligand for the Natural Cytotoxicity Receptor NKp44. J Immunol. 187(11):5693-702, 2011

44. Jarahian M., Fiedler M., Cohnen A., Djandji D., Hämmerling GJ., Gati C., Cerwenka A., Turner, PC., Moyer, RW., Watzl, C., Hengel, H., Momburg, F., Modulation of NKp30- and NKp46-Mediated Natural Killer Cell Responses by Poxviral Hemagglutinin, PLoS Pathogens 7(8), 2011  

45. Ni Y., Galani IE., Cerwenka A., Schirrmacher V., Fournier P.,  Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity, Vaccine, 29(6):1185-93, 2011

46. Liesz A., Zhou W., Mracskó E., Karcher S., Bauer H., Schwarting S., Sun L., Bruder D., Stegemann S., Cerwenka A., Sommer C., Dalpke AH., and Veltkamp R. Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke, Brain, 134(Pt 3):704-20, 2011

47. Textor S, Accardi R, Havlova T, Hussain I, Sylla BS, Gissmann L and Cerwenka A. NF-κ B-dependent up-regulation of ICAM-1 by HPV16-E6/E7 facilitates NK cell/ target cell interaction. Int J Cancer 128(5):1104-13, 2011

48. Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A.  Human NK cells are alerted to induction of p53 in cancer cells by up-regulation of the NKG2D-ligands ULBP1 and ULBP2, Cancer Res.  71(18):5998-6009, 2011

49. Ormsby T, Schlecker E, Ferdin J, Tessarz AS, Angelisová P, Köprülü AD, Borte M, Warnatz K, Schulze I, Ellmeier, Hořejší V and Cerwenka A. Btk is a positive regulator in the TREM-1/DAP12 signalling pathway. Blood 118(4):936-45, 2011

2012

50. Lehner M, Götz G, Proff J, Schaft N, Dörrie J, Full F, Ensser A, Muller Y, Cerwenka A, Abken H, Parolini O, Ambros P, Kovar H, Holter W.  Redirecting T Cells to Ewing´s Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection, PLoS ONE 7(2), 2012

51. Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, Cerwenka A. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favouring tumor growth. J.Immunol. 189(12):5602-5611, 2012

52. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18 preactivated NK cells against established tumors. J Exp Med 209(13):2351-2365, 2012

2013

53. Stojanovic A, Correia MP, Cerwenka A. Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron. 6(2):135-146, 2013

54. Ni J, Miller M, Stojanovic A Cerwenka A. Towards the next generation of NK cell based adoptive immunotherapy of cancer. Oncoimmunology 2(4):e23811, 2013

55. Momburg F, Watzl C, Cerwenka A. NK cells - versatile tools for viral defense and cancer treatment. Eur. J. Immunol. 43(4):860-863, 2013

56. Cohnen A, Chiang S, Stojanovic A, Schmidt H, Saftig P, Janßen O, Cerwenka A, Bryceson YT and Watzl C.  Surface CD107a/LAMP-1 protects Natural Killer cells from degranulation-associated damage. Blood 122(8):1411-8, 2013

57. Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M, Cerwenka A. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 122(5):684-693, 2013

58. Roelle A, Pollmann J, Cerwenka A. Memory of infections – an emerging role for Natural Killer Cells. PloS Pathogens 9(9), e1003548, 2013  

59. Ullrich E, Koch J, Cerwenka A, Steinle A. New prospects on the NKG2D/NKG2D-ligand system for oncology. Oncoimmunology, 2013 Oct 1;2(10):e26097

2014

60. Stojanovic A, Fiegler N, Brunner-Weinzierl M and Cerwenka A. CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN- production in response to mature dendritic cells, J Immunol. 2014 May 1;192(9):4184-91

61. Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, Textor S, Cerwenka A. 2014, Metalloprotease-mediated shedding of B7-H6, the ligand of the activating receptor NKp30, from tumor cells, Cancer Research, 2014, Jul 1;74(13):3429-40. doi: 10.1158/0008-5472.CAN-13-3017. Epub 2014 Apr 29

62. Chronic liver inflammation and hepatocellular carcinogenesis are independent of S100A9.
De Ponti A, Wiechert L, Stojanovic A, Longerich T, Marhenke S, Hogg N, Vogel A, Cerwenka A, Schirmacher P, Hess J, Angel P. Int J Cancer. 2014 Oct 21. doi: 10.1002/ijc.29282. [Epub ahead of print]

63. Rölle A, Pollmann J, Ewen E, Halenius A, Hengel H, Cerwenka A. 2014. IL-12 producing monocytes and HLA-E drive NKG2C+ NK cell expansion in HCMV infection, J. Clin. Invest. Nov 10. pii: 77440. doi: 10.1172/JCI77440. [Epub ahead of print]

64. Mracsko E, Liesz A, Stojanovic A, Lou WP, Osswald M, Zhou W, Karcher S, Winkler F, Martin-Villalba A, Cerwenka A, Veltkamp R. 2014. Antigen dependently activated cluster of differentiation 8-positive T cells cause perforin-mediated neurotoxicity in experimental stroke. J Neurosci. 2014 Dec 10;34(50):16784-95.

2015

65. Yossef R, Gur C, Shemesh A, Guttman O, Hadad U, Nedvetzki S, Miletić A, Nalbandyan K, Cerwenka A, Jonjic S, Mandelboim O, Porgador A. 2015. Targeting natural killer cells reactivity by employing antibody to NKp46: Implications for type 1 Diabetis. PLoS One. 2015 Feb 26;10(2):e0118936

66. Hölsken O, Miller M, Cerwenka A. 2015. Exploting natural killer cells for therapy of melanoma. J Dtsch Dermatol Ges. 2015 Jan;13(1):23-9

67. Steinle A, Cerwenka A. 2015. Immunology. Multiplying cancer immunity. Science. 2015 Apr 3;348(6230):45-6.

68. De Ponti A, Wiechert L, Stojanovic A, Longerich T, Marhenke S, Hogg N, Vogel A, Cerwenka A, Schirmacher P, Hess J, Angel P. 2015. Chronic liver inflammation and hepatocellular carcinogenesis are independent of S100A9. Int J Cancer. May 15;136(10):2458-63. doi: 10.1002/ijc.29282. Epub 2014 Nov 13.

69. Giannattasio A, Weil S, Kloess S, Ansari N, Stelzer EH, Cerwenka A, Steinle A, Koehl U, Koch J. 2015. Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids.
BMC Cancer. May 3;15:351. doi: 10.1186/s12885-015-1321-y.

70. Granzin M, Soltenborn S, Müller S, Kollet J, Berg M, Cerwenka A, Childs RW, Huppert V. 2015. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy. May;17(5):621-32. doi: 10.1016/j.jcyt.2015.03.611.

71. Merkt W, Sturm P, Lasitschka F, Tretter T, Watzl C, Saure D, Hundemer M, Schwenger V, Blank N, Lorenz HM, Cerwenka A. 2015. Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage. Arthritis Res Ther. 2015 Nov 21;17(1):337. doi: 10.1186/s13075-015-0851-7.

2016

72. Cerwenka A, Lanier LL, 2016, NK cell memory in viral infection, inflammation and cancer, Nature Immunology Reviews; Feb;16(2):112-23. doi: 10.1038/nri.2015.9. Epub 2016 Jan 25

73. Gdynia G, Sauer SW, Kopitz J, Fuchs D, Duglova D, Ruppert T, Miller M, Pahl J, Cerwenka A, Enders M, Mairbäurl H, Kamiński MM, Penzel R, Zhang C, Fuller JC, Wade RC, Benner A, Chang-Claude J, Brenner H, Hoffmeister M, Zentgraf HW, Schirmacher P, Roth W. 2015, The HMGB1 protein induces a new type of metabolic tumor cell death by blocking aerobic respiration; Nat Commun. 2016 Mar 7;7:10764. doi: 10.1038/ncomms10764.

74. Textor S, Bossler F, Henrich KO, Gartlgruber M,  Pollmann J, Fiegler N, Arnold A, Westermann F, Waldburger N, Breuhahn K, Golfier S, Witzens-Harig M and Cerwenka A, 2015, The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells, Oncoimmunology.
2016 Jul 28;5(7):e1116674. doi: 10.1080/2162402X.2015.1116674. eCollection 2016 Jul.

75. Ni J, Cerwenka A. STAT5 Loss Awakens the Dark Force in Natural Killer Cells. Cancer Discov. 2016 Apr;6(4):347-9. doi: 10.1158/2159-8290.CD-16-0247.

76. Ni J, Hölsken O, Miller M, Hammer Q, Luetke-Eversloh M, Romagnani C, Cerwenka A. Adoptively transferred natural killer cells maintain long-term antitumor activity by epigenetic imprinting and CD4+ T cell help. Oncoimmunology. 2016 Aug 5;5(9):e1219009. eCollection 2016.

77. Granzin M, Stojanovic A, Miller M, Childs R, Huppert V, Cerwenka A. Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma. Oncoimmunology. 2016 Aug 5;5(9):e1219007. eCollection 2016.

78. Merkt W, Claus M, Blank N, Hundemer M, Cerwenka A, Lorenz HM, Watzl C. Active but not inactive granulomatosis with polyangiitis is associated with decreased and phenotypically and functionally altered CD56(dim) natural killer cells. Arthritis Res Ther. 2016 Sep 13;18(1):204. doi: 10.1186/s13075-016-1098-7.

79. Rölle A, Halenius A, Ewen EM, Cerwenka A, Hengel H, Momburg F. CD2-CD58 interactions are pivotal for the activation and function of adaptive natural killer cells in human cytomegalovirus infection. Eur J Immunol. 2016 Oct;46(10):2420-2425. doi: 10.1002/eji.201646492. Epub 2016 Aug 29.

80. Zysset D, Weber B, Rihs S, Brasseit J, Freigang S, Riether C, Banz Y, Cerwenka A, Simillion C, Marques-Vidal P, Ochsenbein AF, Saurer L, Mueller C. TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. Nat Commun. 2016 Oct 20;7:13151. doi: 10.1038/ncomms13151.

2017

81. Pollmann J, Rölle A, Hofmann M, Cerwenka A.: Hepatitis C Virus and Human Cytomegalovirus-Natural Killer Cell Subsets in Persistent Viral Infections. Front Immunol. 2017 May 17;8:566. doi: 10.3389/fimmu.2017.00566. eCollection 2017. Review.

82. Chretien AS, Fauriat C, Orlanducci F, Rey J, Borg GB, Gautherot E, Granjeaud S, Demerle C, Hamel JF, Cerwenka A, von Strandmann EP, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Olive D. NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. Oncotarget. 2017 May 10. doi: 10.18632/oncotarget.17747. [Epub ahead of print]

83. Granzin M, Wagner J, Köhl U, Cerwenka A, Huppert V, Ullrich E. Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation. Front Immunol. 2017 Apr 26;8:458. doi: 10.3389/fimmu.2017.00458. eCollection 2017. Review.

84. Pahl J, Cerwenka A. Tricking the balance: NK cells in anti-cancer immunity. Immunobiology. 2017 Jan;222(1):11-20. doi: 10.1016/j.imbio.2015.07.012. Epub 2015 Jul 26. Review.

Kontextspalte